Visceral Leishmaniasis and HIV coinfection in East Africa
- PMID: 24968313
- PMCID: PMC4072530
- DOI: 10.1371/journal.pntd.0002869
Visceral Leishmaniasis and HIV coinfection in East Africa
Abstract
Visceral Leishmaniasis (VL) is an important protozoan opportunistic disease in HIV patients in endemic areas. East Africa is second to the Indian subcontinent in the global VL caseload and first in VL-HIV coinfection rate. Because of the alteration in the disease course, the diagnostic challenges, and the poor treatment responses, VL with HIV coinfection has become a very serious challenge in East Africa today. Field experience with the use of liposomal amphotericin B in combination with miltefosine, followed by secondary prophylaxis and antiretroviral drugs, looks promising. However, this needs to be confirmed through clinical trials. Better diagnostic and follow-up methods for relapse and prediction of relapse should also be looked for. Basic research to understand the immunological interaction of the two infections may ultimately help to improve the management of the coinfection.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
-
- Seaman J, Mercer AJ, Sondorp E (1996) The epidemic of visceral leishmaniasis in western upper Nile, Southern Sudan: Course and impact from 1984 to 1994. Int J Epidemiol 25: 862–871. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical